Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DataMeds AI, Inc.WGRX · Entity 8434 | Chief Executive Officer | March 21, 2025 | March 25, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DataMeds AI, Inc.
Report date March 21, 2025 · Filed March 25, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, Par Value $0.0001SEC Table I · non-derivative | Direct | 9,044,720 |
Reported balance
After 2025-03-21 transaction · row 1
1 source rowRow 1 · 2025-03-21 · Grant · Acquired 9,000,000 · Balance 9,044,720 F1: Shares of restricted stock issued pursuant to the Wellgistics Health, Inc. Amended and Restated 2023 Equity Incentive Plan. The shares shall fully vest solely upon the achievement of certain financial metrics for the years ending December 31, 2025, 2026, and 2027. The first vesting opportunity is during the first quarter of 2026. |
| Common Stock, Par Value $0.0001SEC Table I · non-derivative | IndirectBy Strategix Global LLC | 2,279,621 |
Reported balance
Holding disclosure · report date 2025-03-21 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,279,621 |
| Common Stock, Par Value $0.0001SEC Table I · non-derivative | IndirectBy Nomad Capital LLC | 199,967 |
Reported balance
Holding disclosure · report date 2025-03-21 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 199,967 |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of restricted stock issued pursuant to the Wellgistics Health, Inc. Amended and Restated 2023 Equity Incentive Plan. The shares shall fully vest solely upon the achievement of certain financial metrics for the years ending December 31, 2025, 2026, and 2027. The first vesting opportunity is during the first quarter of 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 21, 2025 Filed Mar 25, 2025 11:59 UTC | DataMeds AI, Inc. WGRX · Entity 8434 | GrantCommon Stock, Par Value $0.0001 | 9,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-000551 · ownership.xml · nonDerivative · entry 1 Norton Brian · CIK 0002059336 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,044,720 F1 · shares: Shares of restricted stock issued pursuant to the Wellgistics Health, Inc. Amended and Restated 2023 Equity Incentive Plan. The shares shall fully vest solely upon the achievement of certain financial metrics for the years ending December 31, 2025, 2026, and 2027. The first vesting opportunity is during the first quarter of 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.